Novel Antibody-Drug Conjugate Eliminates Residual Cancer Cells in Majority of Patients with B-Cell ALL

Novel antibody-drug conjugate eliminates residual cancer cells in majority of patients with B-cell ALL

Researchers at The University of Texas MD Anderson Cancer Center were able to eradicate measurable residual disease (MRD) in B-cell acute lymphoblastic leukemia (ALL) patients, a critical step in improving long-term survival outcomes, by treating them with the antibody-drug conjugate (ADC) inotuzumab ozogamicin.

Novel leukemia therapy successfully eradicates measurable residual disease

Researchers at The University of Texas MD Anderson Cancer Center were able to eradicate measurable residual disease (MRD) in B-cell acute lymphoblastic leukemia (ALL) patients, a critical step in improving long-term survival outcomes, by treating with the antibody-drug conjugate (ADC) inotuzumab ozogamicin.

Inotuzumab Ozogamicin Shows MRD Clearance in B-Cell ALL Trial

Data from a phase 2 trial show the potential of inotuzumab ozogamicin to deepen remissions in patients with B-cell acute lymphoblastic leukemia.

Antibody Drug Conjugate Treatment Destroys Hidden B Cell Leukemia

By using the antibody-drug conjugate (ADC) inotuzumab ozogamicin to treat B-cell acute lymphoblastic leukemia (ALL) patients, researchers at The University of Texas MD Anderson Cancer Center were able to eliminate measurable residual disease (MRD), a crucial step in enhancing long-term survival outcomes.